Draper Asset Management’s CRISPR Therapeutics CRSP Stock Holding History

Draper Asset Management’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-2,700	Closed	-$9.29K	–	32
2023 Q4	$9.29K	Buy	2,700 +1,000	+59%	+$55.3K	0.01%	32
2023 Q3	$1.81K	Hold	1,700	–	–	﹤0.01%	35
2023 Q2	$9.7K	Hold	1,700	–	–	0.01%	29
2023 Q1	$4.7K	Sell	1,700 -600	-26%	-$29.1K	0.01%	31
2022 Q4	$7.55K	Buy	+2,300	New	+$122K	0.01%	45
2022 Q3	–	Sell	-2,300	Closed	-$31K	–	27
2022 Q2	$31K	Buy	2,300 +2,000	+667%	+$118K	0.04%	38
2022 Q1	$1K	Hold	300	–	–	﹤0.01%	43
2021 Q4	$3K	Buy	+300	New	+$26.2K	﹤0.01%	49

Other funds holding CRSP

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Draper Asset Management's CRSP Position: Q3 2024 in Review

Draper Asset Management sold out of CRISPR Therapeutics (CRSP) in Q3 2024, closing a stake of 7,892 shares — an estimated $426K sold.

Draper Asset Management first reported a position in CRSP in Q4 2020 and held it in 15 quarters. The position peaked at $776K in Q2 2021. 416 funds tracked by Wall St. Rank hold CRSP as of Q3 2024.

Draper Asset Management reported no remaining CRISPR Therapeutics position as of Q3 2024 after selling out during the quarter.
Draper Asset Management sold 7,892 CRISPR Therapeutics shares in Q3 2024, an estimated $426K.
Draper Asset Management first reported a position in CRISPR Therapeutics in Q4 2020 and held it in 15 quarters.
Draper Asset Management's CRISPR Therapeutics position peaked at $776K in Q2 2021.
416 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2024.

Based on Draper Asset Management's 13F filing for Q3 2024, filed 12 Nov 2024.